RPRX
Royalty Pharma plc - Ordinary Shares - Class A

7,301
Mkt Cap
$26.07B
Volume
5.41M
52W High
$45.91
52W Low
$29.66
PE Ratio
25.38
RPRX Fundamentals
Price
$45.19
Prev Close
$44.80
Open
$44.80
50D MA
$40.42
Beta
0.34
Avg. Volume
3.85M
EPS (Annual)
$1.78
P/B
2.99
Rev/Employee
$23.78M
$33,378.10
Loading...
Loading...
News
all
press releases
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy
Wall Street Zen downgraded shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX
New South Capital Management Inc. lifted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 1.1% in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX
Cookson Peirce & Co. Inc. raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 988.3% during the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Should You Buy...
MarketBeat·4d ago
News Placeholder
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Misses Expectations By $0.90 EPS
Royalty Pharma (NASDAQ:RPRX - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the...
MarketBeat·4d ago
News Placeholder
Royalty Pharma Q4 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) executives highlighted what they described as a landmark year in 2025, pointing to double-digit top-line growth, continued capital deployment into new royalty deals, and...
MarketBeat·5d ago
News Placeholder
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·5d ago
News Placeholder
Royalty Pharma Plc Bottom Line Advances In Q4
(RTTNews) - Royalty Pharma plc (RPRX) announced earnings for its fourth quarter that Increased from the same period last year...
Nasdaq News: Markets·5d ago
News Placeholder
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
read more...
Benzinga·5d ago
News Placeholder
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Zacks·6d ago
<
1
2
...
>

Latest RPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.